<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916379</url>
  </required_header>
  <id_info>
    <org_study_id>MCHOB</org_study_id>
    <nct_id>NCT04916379</nct_id>
  </id_info>
  <brief_title>Effect of Momordica Charantia Administration on Anthropometric Indicators in Patients With Obesity</brief_title>
  <official_title>Effect of Momordica Charantia Administration on Anthropometric Indicators in Patients With Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Momordica charantia has shown to exert anti-obesity effects through numerous mechanisms of&#xD;
      action described in preclinical studies. Important reductions in body weight and other&#xD;
      anthropometric indicators have been reported in clinical trials. However, these beneficial&#xD;
      effects of Momordica charantia on obesity have been observed mainly in type 2 diabetes&#xD;
      mellitus patients. The purpose of this study is to evaluate the effect of Momordica charantia&#xD;
      administration on anthropometric indicators in patients with obesity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo controlled clinical trial is carried out in 24 patients&#xD;
      with obesity according to the body mass index.&#xD;
&#xD;
      Patients are assigned to two different arms: one group receives Momordica charantia, 2&#xD;
      capsules with 500 mg twice daily before breakfast and dinner for 12 weeks or placebo, under&#xD;
      the same scheme of treatment.&#xD;
&#xD;
      Body weight, body mass index, waist circumference, body fat percentage and other clinical and&#xD;
      laboratory parameters are evaluated.&#xD;
&#xD;
      This protocol is approved by a local ethics committee and written informed consent will be&#xD;
      obtained from all volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 21, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline body mass index (BMI) at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>BMI is calculated at baseline and after 12 weeks with the Quetelet index formula</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline body weight (BW) at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>BW is evaluated at baseline and after 12 weeks with an electric bioimpedance digital scale (Model TBF-300 A; Tanita Corporation of America Inc., Arlington Heights, IL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline fat mass at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Fat mass is measured at baseline and after 12 weeks with an electric bioimpedance digital scale (Model TBF-300 A; Tanita Corporation of America Inc., Arlington Heights, IL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline waist circumference (WC) at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>WC is evaluated at baseline and after 12 weeks with a flexible tape in the midpoint between the lowest rib and the iliac crest</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline fasting plasma glucose (FPG) at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>FPG is evaluated at baseline and after 12 weeks with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline total cholesterol at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Total cholesterol is evaluated at baseline and after 12 weeks with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline triglycerides at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Triglycerides are evaluated at baseline and after 12 weeks with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline high density lipoprotein cholesterol (HDL-c) at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>HDL-c is evaluated at baseline and after 12 weeks with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline low density lipoprotein cholesterol (LDL-c) at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>LDL-c is evaluated at baseline and after 12 weeks with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline very low density lipoprotein (VLDL) at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>VLDL is calculated at baseline and after 12 weeks as triglycerides/5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline creatinine at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Creatinine is evaluated at baseline and after 12 weeks with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline uric acid at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Uric acid is evaluated at baseline and after 12 weeks with enzymatic-colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline alanine aminotransferase (ALT) at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>ALT is evaluated at baseline and after 12 weeks with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline aspartate aminotransferase (AST) at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>AST is evaluated at baseline and after 12 weeks with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline systolic blood pressure at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Systolic blood pressure is measured at baseline and after 12 weeks with a digital sphygmomanometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline diastolic blood pressure at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Diastolic blood pressure is measured at baseline and after 12 weeks with a digital sphygmomanometer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Momordica charantia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 500 mg capsules of Momordica charantia twice daily before breakfast and dinner for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Momordica charantia</intervention_name>
    <description>Momordica Charantia: 2000 mg per day for 12 weeks</description>
    <arm_group_label>Momordica charantia</arm_group_label>
    <other_name>Bitter melon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: 2000 mg per day for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Calcined magnesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of obesity type I according to body mass index (IMC: 30.0 - 34.9 kg/m2)&#xD;
&#xD;
          -  Body weight without variations above or under 5% in the last three months before&#xD;
             entering the study&#xD;
&#xD;
          -  Fasting plasma glucose: &lt;126 mg/dL&#xD;
&#xD;
          -  Total cholesterol: &lt;240 mg/dL&#xD;
&#xD;
          -  Triglycerides: &lt;400 mg/dL&#xD;
&#xD;
          -  Women in childbearing years must have a contraceptive method&#xD;
&#xD;
          -  Letter of consent and release signed by each patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with confirmed or suspected pregnancy&#xD;
&#xD;
          -  Women under lactation and/or puerperium&#xD;
&#xD;
          -  Known uncontrolled renal, hepatic, cardiovascular or thyroid disease&#xD;
&#xD;
          -  Physical impossibility for taking pills&#xD;
&#xD;
          -  Known hypersensibility to the Momordica charantia or placebo&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marisol Cortez Navarrete, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>August 29, 2021</last_update_submitted>
  <last_update_submitted_qc>August 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Marisol Cortez Navarrete</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Momordica charantia</keyword>
  <keyword>Bitter melon</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

